TRIAL OF TOPIRAMATE IN AMYOTROPHIC LATERAL SCLEROSIS

$0M01FY2000RRNIH

University Of Vermont &St Agric College, Burlington VT

Investigators

Linked publications & trials

Paper 36923963 Paper 35108352 Paper 34918583 Paper 29243507 Paper 26893016 Paper 26519084 Paper 26324406 Paper 26156077 Paper 26123902 Paper 25757805 Paper 25576820 Paper 25567808 Paper 25397604 Paper 24821412 Paper 24790014 Paper 24593827 Paper 24582471 Paper 23887900 Paper 23840001 Paper 23772359 Paper 23392279 Paper 23279924 Paper 23106931 Paper 23106930 Paper 23106929 Paper 23106928 Paper 23106927 Paper 23106926 Paper 23106925 Paper 23106924 Paper 23106923 Paper 23010380 Paper 22832417 Paper 22517450 Paper 22232050 Paper 21929806 Paper 21782230 Paper 21036512 Paper 20840188 Paper 20724360 Paper 20566621 Paper 20559306 Paper 20554818 Paper 20528773 Paper 20444630 Paper 20228381 Paper 19958536 Paper 19940516 Paper 19923572 Paper 19883745 Paper 19842970 Paper 19590456 Paper 19531800 Paper 19442460 Paper 19433757 Paper 19327849 Paper 19192424 Paper 18957505 Paper 18843517 Paper 18703999 Paper 18667190 Paper 18483477 Paper 18413671 Paper 18248941 Paper 18223608 Paper 18060051 Paper 17998017 Paper 17964576 Paper 17666599 Paper 17636080 Paper 17513423 Paper 17478172 Paper 17412329 Paper 17364435 Paper 17306648 Paper 16885375 Paper 16873787 Paper 16802291 Paper 16316172 Paper 16194110 Paper 16134292 Paper 16087974 Paper 16079954 Paper 16061752 Paper 16006430 Paper 15930473 Paper 15882468 Paper 15571445 Paper 15550321 Paper 15173432 Paper 14594814 Paper 12939417 Paper 12684732 Paper 12510745 Paper 12095664 Paper 11717207 Paper 11533345 Paper 11408248 Paper 11255931 Paper 10899371

Abstract

The study will evaluate the safety and effectiveness of Topiramate treatment in amyotrophic lateral sclerosis (ALS). This is a double-blind randomized, placebo-controlled 12 month trial. The objective is to determine whether topiramate slows disease progression in patients with ALS. The primary outcome measure is change in disease progression rate as measured by the maximum voluntary isometric contraction strength of eight arm muscle groups. Secondary endpoints include the rate of decline of forced vital capacity, grip strength, the change in the ALS functional rating scale, and survival.

View original record on NIH RePORTER →